Opthea (OPT) Competitors $3.41 0.00 (0.00%) As of 06/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. BLTE, HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, IMCR, and GLPGShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Immunocore (IMCR), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore Galapagos Belite Bio (NASDAQ:BLTE) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment. Do analysts rate BLTE or OPT? Belite Bio presently has a consensus target price of $96.67, indicating a potential upside of 57.44%. Opthea has a consensus target price of $1.33, indicating a potential downside of 60.90%. Given Belite Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Belite Bio is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Which has higher valuation & earnings, BLTE or OPT? Belite Bio has higher earnings, but lower revenue than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$31.63M-$1.36-45.15Opthea$87.67K5,986.77-$220.24MN/AN/A Does the media refer more to BLTE or OPT? In the previous week, Belite Bio had 6 more articles in the media than Opthea. MarketBeat recorded 10 mentions for Belite Bio and 4 mentions for Opthea. Belite Bio's average media sentiment score of 0.69 beat Opthea's score of 0.53 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opthea 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is BLTE or OPT more profitable? Opthea's return on equity of 0.00% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -31.94% -30.73% Opthea N/A N/A N/A Does the MarketBeat Community believe in BLTE or OPT? Belite Bio received 17 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 94.74% of users gave Belite Bio an outperform vote while only 48.72% of users gave Opthea an outperform vote. CompanyUnderperformOutperformBelite BioOutperform Votes3694.74% Underperform Votes25.26%OptheaOutperform Votes1948.72% Underperform Votes2051.28% Which has more risk & volatility, BLTE or OPT? Belite Bio has a beta of -1.44, indicating that its share price is 244% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Do institutionals & insiders have more ownership in BLTE or OPT? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryBelite Bio beats Opthea on 9 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$3.10B$5.60B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E RatioN/A33.2727.2320.02Price / Sales5,986.77468.94417.65154.33Price / CashN/A168.6838.2534.64Price / Book-6.093.447.124.70Net Income-$220.24M-$72.35M$3.23B$247.97M7 Day PerformanceN/A7.57%2.74%2.64%1 Month PerformanceN/A18.09%8.94%6.39%1 Year PerformanceN/A-16.71%31.59%13.95% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.8265 of 5 stars$3.41flat$1.33-60.9%+36.4%$524.84M$87.67K0.008News CoverageGap UpBLTEBelite Bio2.3058 of 5 stars$65.02+0.2%$96.67+48.7%+25.2%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7782 of 5 stars$35.56+3.1%$53.00+49.0%+18.4%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2592 of 5 stars$27.92+2.0%$38.80+39.0%+61.1%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.6777 of 5 stars$40.46-2.0%$61.14+51.1%+2.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.354 of 5 stars$13.96+5.4%$33.71+141.5%-29.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.5187 of 5 stars$26.59+3.8%$58.22+119.0%-25.6%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.9091 of 5 stars$31.74+67.5%$65.00+104.8%-42.5%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+33.6%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore3.0627 of 5 stars$38.65+5.6%$58.89+52.4%-13.5%$1.94B$333.58M-40.68320Analyst RevisionHigh Trading VolumeGLPGGalapagos0.404 of 5 stars$29.20+1.5%$25.33-13.2%+8.2%$1.92B$288.19M0.001,310Positive News Related Companies and Tools Related Companies BLTE Alternatives HRMY Alternatives KNSA Alternatives VCEL Alternatives DNLI Alternatives CGON Alternatives VERA Alternatives GMTX Alternatives IMCR Alternatives GLPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
